JP2016523511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523511A5 JP2016523511A5 JP2016506657A JP2016506657A JP2016523511A5 JP 2016523511 A5 JP2016523511 A5 JP 2016523511A5 JP 2016506657 A JP2016506657 A JP 2016506657A JP 2016506657 A JP2016506657 A JP 2016506657A JP 2016523511 A5 JP2016523511 A5 JP 2016523511A5
- Authority
- JP
- Japan
- Prior art keywords
- pairs
- indicator
- region
- cancer cells
- loh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019085187A JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361809105P | 2013-04-05 | 2013-04-05 | |
| US61/809,105 | 2013-04-05 | ||
| US201361913762P | 2013-12-09 | 2013-12-09 | |
| US61/913,762 | 2013-12-09 | ||
| PCT/US2014/033014 WO2014165785A2 (en) | 2013-04-05 | 2014-04-04 | Methods and materials for assessing homologous recombination deficiency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019085187A Division JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523511A JP2016523511A (ja) | 2016-08-12 |
| JP2016523511A5 true JP2016523511A5 (cg-RX-API-DMAC7.html) | 2017-03-16 |
| JP6625045B2 JP6625045B2 (ja) | 2019-12-25 |
Family
ID=51659359
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016506657A Active JP6625045B2 (ja) | 2013-04-05 | 2014-04-04 | 相同組換え欠損を評価するための方法および材料 |
| JP2019085187A Active JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
| JP2020194936A Active JP7522643B2 (ja) | 2013-04-05 | 2020-11-25 | 相同組換え欠損を評価するための方法および材料 |
| JP2022169085A Active JP7641938B2 (ja) | 2013-04-05 | 2022-10-21 | 相同組換え欠損を評価するための方法および材料 |
| JP2025027653A Pending JP2025090619A (ja) | 2013-04-05 | 2025-02-25 | 相同組換え欠損を評価するための方法および材料 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019085187A Active JP7522539B2 (ja) | 2013-04-05 | 2019-04-26 | 相同組換え欠損を評価するための方法および材料 |
| JP2020194936A Active JP7522643B2 (ja) | 2013-04-05 | 2020-11-25 | 相同組換え欠損を評価するための方法および材料 |
| JP2022169085A Active JP7641938B2 (ja) | 2013-04-05 | 2022-10-21 | 相同組換え欠損を評価するための方法および材料 |
| JP2025027653A Pending JP2025090619A (ja) | 2013-04-05 | 2025-02-25 | 相同組換え欠損を評価するための方法および材料 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20140363521A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2981624B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6625045B2 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014248007B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2908745C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2981624T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2777228T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2981624T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014165785A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012027224A1 (en) | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| EP3225697A3 (en) | 2010-12-30 | 2017-11-22 | Foundation Medicine, Inc. | Optimization of multigene analysis of tumor samples |
| WO2012174378A2 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| CN107267598B (zh) | 2011-12-21 | 2022-03-25 | 美瑞德生物工程公司 | 用于评估杂合性丢失的方法与材料 |
| EP3415915B1 (en) | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| CA3126823C (en) | 2012-06-07 | 2023-04-04 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EP2981624B1 (en) * | 2013-04-05 | 2019-12-18 | Myriad Genetics, Inc. | Methods for assessing homologous recombination deficiency and predicting response to cancer treatment |
| EP3080292B1 (en) | 2013-12-09 | 2022-02-02 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US10545151B2 (en) | 2014-02-21 | 2020-01-28 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| ES2946251T3 (es) | 2014-08-15 | 2023-07-14 | Myriad Genetics Inc | Métodos y materiales para evaluar la deficiencia de recombinación homóloga |
| CA2967447C (en) * | 2014-12-05 | 2025-07-08 | Foundation Medicine, Inc. | MULTIGEN ANALYSIS OF TUMOR SAMPLES |
| EP3230472A4 (en) * | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
| WO2016185406A1 (en) | 2015-05-19 | 2016-11-24 | Nadathur Estates Pvt. Ltd. | Method for identification of a deficient brca1 function |
| JP7043412B2 (ja) | 2015-11-03 | 2022-03-29 | エピック サイエンシス， インコーポレイテッド | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
| WO2017106365A1 (en) * | 2015-12-14 | 2017-06-22 | Myriad Genetics, Inc. | Methods for measuring mutation load |
| WO2017120324A1 (en) * | 2016-01-06 | 2017-07-13 | Epic Sciences, Inc. | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
| WO2017165270A1 (en) * | 2016-03-21 | 2017-09-28 | Myriad Genetics, Inc. | Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer |
| WO2017178509A1 (en) | 2016-04-12 | 2017-10-19 | Xentech | Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients |
| WO2017191076A1 (en) | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| JP7224185B2 (ja) * | 2016-05-01 | 2023-02-17 | ゲノム・リサーチ・リミテッド | Ｄｎａサンプルを特徴付ける方法 |
| GB2555765A (en) | 2016-05-01 | 2018-05-16 | Genome Res Ltd | Method of detecting a mutational signature in a sample |
| KR20230042136A (ko) * | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| KR20210035167A (ko) | 2018-06-11 | 2021-03-31 | 파운데이션 메디신 인코포레이티드 | 게놈 변경을 평가하기 위한 조성물 및 방법 |
| JPWO2020137076A1 (ja) * | 2018-12-28 | 2021-11-11 | 国立大学法人 東京大学 | Ｐａｒｐ阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法 |
| JP7368483B2 (ja) | 2019-02-12 | 2023-10-24 | テンパス ラブズ，インコーポレイテッド | 相同組換え欠損を推定するための統合された機械学習フレームワーク |
| EP4073805B1 (en) | 2019-12-10 | 2024-07-17 | Tempus AI, Inc. | Systems and methods for predicting homologous recombination deficiency status of a specimen |
| JP2023506084A (ja) * | 2019-12-16 | 2023-02-14 | アジレント・テクノロジーズ・インク | ゲノム瘢痕アッセイ及び関連する方法 |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| CN111883211B (zh) * | 2020-08-07 | 2021-04-23 | 张哲� | 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法 |
| US11718869B2 (en) * | 2020-08-12 | 2023-08-08 | Zhenyue Biotechnology Jiangsu Co., Ltd. | Method and kit for determining genome instability based on next generation sequencing (NGS) |
| CN112410423B (zh) * | 2020-11-03 | 2021-08-13 | 南京世和基因生物技术股份有限公司 | 同源重组缺失的标志物、检测方法以及检测系统 |
| EP4274908A1 (en) * | 2021-01-10 | 2023-11-15 | Act Genomics (IP) Limited | Homologous recombination deficiency determining method and kit thereof |
| BE1029144B1 (fr) | 2021-02-25 | 2022-09-20 | Oncodna | Méthode de caracterisation d'une tumeur à l'aide d'un séquençage ciblé |
| CN112820351A (zh) * | 2021-03-01 | 2021-05-18 | 江苏医联生物科技有限公司 | 检测肿瘤患者的突变和hrd评分指导用药的方法 |
| EP4360094A4 (en) * | 2021-06-25 | 2025-04-23 | Foundation Medicine, Inc. | SYSTEM AND METHOD FOR CLASSIFYING AN APPROVED REPAIR DEFICIENCY |
| AR127880A1 (es) * | 2021-12-08 | 2024-03-06 | Myriad Genetics Inc | Métodos y materiales para evaluar la deficiencia de recombinación homóloga en subtipos de cáncer de mama |
| KR102523938B1 (ko) * | 2022-02-04 | 2023-04-19 | 가톨릭대학교 산학협력단 | 상동 재조합 결핍증 예측 모델의 모델링 방법 |
| EP4605937A1 (en) | 2022-10-19 | 2025-08-27 | Vib Vzw | Method of determining loss of heterozygosity status of a tumor |
| WO2025078387A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
| WO2025078404A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| NZ245112A (en) | 1991-11-15 | 1995-07-26 | Smithkline Beecham Corp | Pharmaceutical composition comprising a camptothecin analog and a platinum coordination compound |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| ATE478664T1 (de) | 2000-12-01 | 2010-09-15 | Eisai Inc | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| US7754684B2 (en) | 2003-06-11 | 2010-07-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| US7485707B2 (en) | 2003-07-02 | 2009-02-03 | Solux Corporation | Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| ATE454893T1 (de) | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
| WO2005016946A2 (en) | 2003-08-13 | 2005-02-24 | University Of South Florida | Platinum complexes for the treatment of tumors |
| CN101495459A (zh) | 2005-06-30 | 2009-07-29 | 比奥纽默里克药物公司 | 单吡咯配体铂类似物 |
| KR100925337B1 (ko) * | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| DK3327148T3 (da) | 2010-06-18 | 2021-04-12 | Myriad Genetics Inc | Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle |
| WO2012027224A1 (en) * | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| EP3415915B1 (en) * | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| EP2981624B1 (en) * | 2013-04-05 | 2019-12-18 | Myriad Genetics, Inc. | Methods for assessing homologous recombination deficiency and predicting response to cancer treatment |
-
2014
- 2014-04-04 EP EP14779403.6A patent/EP2981624B1/en active Active
- 2014-04-04 AU AU2014248007A patent/AU2014248007B2/en active Active
- 2014-04-04 EP EP19216740.1A patent/EP3693475A1/en active Pending
- 2014-04-04 JP JP2016506657A patent/JP6625045B2/ja active Active
- 2014-04-04 PT PT147794036T patent/PT2981624T/pt unknown
- 2014-04-04 ES ES14779403T patent/ES2777228T3/es active Active
- 2014-04-04 CA CA2908745A patent/CA2908745C/en active Active
- 2014-04-04 WO PCT/US2014/033014 patent/WO2014165785A2/en not_active Ceased
- 2014-04-04 US US14/245,576 patent/US20140363521A1/en not_active Abandoned
- 2014-04-04 DK DK14779403.6T patent/DK2981624T3/da active
-
2017
- 2017-07-17 US US15/651,652 patent/US20180030544A1/en not_active Abandoned
-
2019
- 2019-04-26 JP JP2019085187A patent/JP7522539B2/ja active Active
-
2020
- 2020-06-17 AU AU2020204028A patent/AU2020204028B2/en active Active
- 2020-11-25 JP JP2020194936A patent/JP7522643B2/ja active Active
-
2021
- 2021-06-21 US US17/353,279 patent/US20210310079A1/en active Pending
-
2022
- 2022-08-04 AU AU2022211880A patent/AU2022211880B2/en active Active
- 2022-10-21 JP JP2022169085A patent/JP7641938B2/ja active Active
-
2025
- 2025-02-25 JP JP2025027653A patent/JP2025090619A/ja active Pending
- 2025-03-24 US US19/088,496 patent/US20250223655A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523511A5 (cg-RX-API-DMAC7.html) | ||
| FI2794907T4 (fi) | Menetelmiä ja materiaaleja heterotsygoottisuuden menettämisen arvioimiseksi | |
| ES2800673T3 (es) | Métodos y materiales para evaluar una deficiencia de recombinación homóloga | |
| ES2777228T3 (es) | Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer | |
| ES2862331T3 (es) | Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer | |
| US20180163271A1 (en) | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity | |
| JP2017512491A5 (cg-RX-API-DMAC7.html) | ||
| JP2016536303A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing | |
| Duraturo et al. | Coexistence of MLH3 germline variants in colon cancer patients belonging to families with Lynch syndrome-associated brain tumors | |
| CN108603231B (zh) | 检测癌症复发的方法 | |
| McDonald et al. | Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation | |
| Haerian et al. | Association of 8q24. 21 rs10505477-rs6983267 haplotype and age at diagnosis of colorectal cancer | |
| Jiang et al. | Identification of a novel fusion gene (HLA-E and HLA-B) by RNA-seq analysis in esophageal squamous cell carcinoma | |
| Fang et al. | ‘Druggable’alterations detected by Ion Torrent in metastatic colorectal cancer patients | |
| Sparano | Defining a role and predicting benefit from platinum-based therapy in breast cancer: an evolving story | |
| Gill | Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies | |
| JP2016123340A (ja) | 膵癌治療感受性の診断方法及び膵癌治療感受性の増強剤 | |
| US20240189450A1 (en) | Methods for treating cancers | |
| Gosia et al. | Long Non-Coding, Micro, and Circular RNAs in Ovarian Cancer Metastasis: Pathways and Treatment Approaches | |
| NZ766822B2 (en) | Methods and materials for assessing homologous recombination deficiency | |
| Madej et al. | Immunomodulatory effect of betulin and its derivatives on IL-6 expression in colorectal cancer cell lines and molecular docking insights | |
| Richardson et al. | Homologous recombination deficiency (HRD) score predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer | |
| Fedorova et al. | The CpG island methylator phenotype (CIMP) in colorectal cancer is associated with energy metabolism alterations | |
| Zhou et al. | Systematic analysis of tumor-infiltrating immune cells in human endometrial cancer: a retrospective study |